Literature DB >> 23752306

The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines.

Jing Mo1, Baocun Sun, Xiulan Zhao, Qiang Gu, Xueyi Dong, Zhiyong Liu, Yuemei Ma, Nan Zhao, Yanrong Liu, Jiadong Chi, Ran Sun.   

Abstract

Cancer stem cells (CSCs) have been identified in various malignancies, and different properties have been examined to characterize CSCs: tumorigenicity in immunocompromised mice, stem cell surface markers, label-retaining properties, and proliferation as nonadherent spheres. This study explored the consistency and efficiency among these methods. Among the melanoma cell lines examined (A375, A875, MUM-2b, and MUM-2c), only A375 and MUM-2c grew as nonadherent spheres and continuously propagated in a defined serum-free medium in vitro. Flow cytometry and immunofluorescence analysis indicated that sphere-derived cells contained a smaller proportion of cells expressing the candidate surface markers of melanoma stem cells such as ABCB5, CD133, CD20 and CD271, and a larger proportion of cells expressing melanocytic differentiation markers such as HMB45 and S100 protein, compared with adherent cells. Surprisingly, the more highly differentiated sphere-derived melanoma cells exhibited increased tumorigenic potential in vivo, as indicated by shorter tumor incubation (A375) and smaller number of cells required to initiate tumor formation (A375 and MUM-2c) compared with those of parental cells. Despite the similarity in histopathological characteristics, the expression profile indicated that xenografts derived from sphere-derived melanoma cells exhibited a more tumorigenic phenotype with respect to the stem or the differentiation markers detected by immunohistochemical analysis. Therefore, sphere formation in nonadherent cultures may not be a preferred surrogate in-vitro method for enriching melanoma stem cells according to candidate markers but may be a favorable condition for activating potential CSCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23752306     DOI: 10.1097/CMR.0b013e32836314e3

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  13 in total

1.  Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

Authors:  Malgorzata Sztiller-Sikorska; Mariusz L Hartman; Beata Talar; Justyna Jakubowska; Izabela Zalesna; Malgorzata Czyz
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

2.  Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation.

Authors:  Anna K Michel; Pratima Nangia-Makker; Avraham Raz; Mary J Cloninger
Journal:  Chembiochem       Date:  2014-08-19       Impact factor: 3.164

Review 3.  Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models.

Authors:  Sayoni Maitra Roy; Vrinda Garg; Sourav Barman; Chitrita Ghosh; Amit Ranjan Maity; Surya K Ghosh
Journal:  Front Bioeng Biotechnol       Date:  2021-12-01

4.  Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation.

Authors:  Muly Tham; Kar Wai Tan; Jo Keeble; Xiaojie Wang; Sandra Hubert; Luke Barron; Nguan Soon Tan; Masashi Kato; Armelle Prevost-Blondel; Veronique Angeli; Jean-Pierre Abastado
Journal:  Oncotarget       Date:  2014-12-15

5.  Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.

Authors:  Lucia Kucerova; Lucia Demkova; Svetlana Skolekova; Roman Bohovic; Miroslava Matuskova
Journal:  BMC Cancer       Date:  2016-05-12       Impact factor: 4.430

6.  Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype.

Authors:  Anne-Marie Bleau; Carolina Zandueta; Miriam Redrado; Susana Martínez-Canarias; Leyre Larzábal; Luis M Montuenga; Alfonso Calvo; Fernando Lecanda
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

8.  Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.

Authors:  Mariusz L Hartman; Beata Talar; Muhammad Zaeem Noman; Anna Gajos-Michniewicz; Salem Chouaib; Malgorzata Czyz
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Authors:  M A Ligtenberg; K Witt; F Galvez-Cancino; A Sette; A Lundqvist; A Lladser; R Kiessling
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

Review 10.  Modeling Melanoma In Vitro and In Vivo.

Authors:  Kimberley A Beaumont; Nethia Mohana-Kumaran; Nikolas K Haass
Journal:  Healthcare (Basel)       Date:  2013-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.